真实临床实践中LABA-LAMA与LABA-ICS治疗COPD的比较有效性与安全性
该研究基于英国CPRD 2002-2015年数据,纳入55岁以上COPD患者,采用时间条件高维倾向评分匹配比较同日启动LABA-LAMA(无ICS)与LABA-ICS(无LAMA)各1977例,随访1年。结果显示两组中重度或重度COPD急性加重风险无显著差异,但LABA-LAMA组重度肺炎住院发生率较低。
要点
- LABA-LAMA与LABA-ICS在预防COPD急性加重方面效果相当。
- LABA-LAMA组重度肺炎住院风险较低,尤其在意向治疗分析中。
- 真实世界中LABA-LAMA可能因安全性优势而更受青睐。
核心结论
- 在真实临床实践中,LABA-LAMA联合吸入器预防COPD急性加重的效果与LABA-ICS联合吸入器相当。
- LABA-LAMA组合可能与较少的重度肺炎相关,因此可能更受青睐。
研究设计与样本
- 基于英国临床实践研究数据链(CPRD)2002-2015年的回顾性队列研究。
- 纳入55岁及以上COPD患者,同日启动LABA-LAMA(无ICS)者与同日启动LABA-ICS(无LAMA)者按时间条件高维倾向评分1:1匹配,各1977例,随访1年。
主要发现
- LABA-LAMA启动者相对LABA-ICS启动者,中重度COPD急性加重的风险比(HR)为1.04(95%CI 0.90-1.20)。
- 重度急性加重的HR为0.94(95%CI 0.65-1.36)。
- 需住院的重度肺炎发生率在LABA-LAMA组较低(HR 0.66;95%CI 0.41-1.05),在意向治疗分析中HR为0.66(95%CI 0.50-0.87)。
临床怎么用
- 对于COPD维持治疗,LABA-LAMA可作为与LABA-ICS等效的选项,且可能降低重度肺炎风险。
- 临床决策时可结合患者肺炎风险等因素考虑优先选择LABA-LAMA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are recommended as initial maintenance treatments for COPD, with their combination (LABA-LAMA) advocated as the disease progresses. Randomized trials comparing the effectiveness of this combination with the alternative combination of LABA with inhaled corticosteroid (LABA-ICS) have reported conflicting data, while there are no real-world comparative effectiveness and safety studies of these regimens in clinical practice settings. METHODS: We identified a cohort of patients with COPD during 2002-2015, age 55 years or older, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating LABA-LAMA on the same day (no ICS) were matched on time-conditional high-dimensional propensity scores with patients initiating LABA-ICS on the same day (no LAMA), and monitored for 1 year for the occurrence of a moderate or severe COPD exacerbation and severe pneumonia. RESULTS: The cohort included 1,977 initiators of LABA-LAMA matched with 1,977 initiators of LABA-ICS. The hazard ratio (HR) of moderate or severe COPD exacerbation associated with LABA-LAMA initiation, relative to LABA-ICS initiation, was 1.04 (95% CI, 0.90-1.20), while for a severe exacerbation it was 0.94 (95% CI, 0.65-1.36). The incidence of severe pneumonia requiring hospitalization was lower with LABA-LAMA initiation (HR, 0.66; 95% CI, 0.41-1.05), particularly in the on-treatment analysis (HR, 0.66; 95% CI, 0.50-0.87). CONCLUSIONS: In a real-world clinical practice setting of COPD treatment, combined LABA-LAMA inhalers appear to be as effective as combined LABA-ICS inhalers in preventing COPD exacerbations. However, a LABA-LAMA combination may be preferred because it is associated with fewer severe pneumonias.
引用
- Suissa S, Dell'Aniello S, Ernst P, et al. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest. 2019. PMID: 30922950. doi:10.1016/j.chest.2019.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。